Jaguar Gene Therapy Closes $139 Million Series B Funding Co-Led By Eli Lilly And Company And Deerfield Management
Jaguar Gene Therapy Closes $139 Million Series B Funding Co-Led By Eli Lilly And Company And Deerfield Management
04/13/21, 4:01 PM
Location
Money raised
$139 million
Round Type
series b
Jaguar Gene Therapy, a company accelerating breakthroughs in gene therapy for patients suffering from severe genetic diseases, today announced it has closed a $139 million Series B funding co-led by Eli Lilly and Company and Deerfield Management. Also participating in the round were ARCH Venture Partners, co-founded by Robert Nelsen and one of the largest early-stage technology venture firms in the United States, Goldman Sachs, and Nolan Capital, the investment fund of former AveXis CEO and current Jaguar Executive Chairman Sean P. Nolan.
Company Info
Location
lake forest, california, united states
Additional Info
Jaguar Gene Therapy, LLC is accelerating breakthroughs in gene therapy for patients suffering from severe genetic diseases. Led by former AveXis leadership, Jaguar leverages a proven management team with the expertise to accelerate the development, manufacturing and commercialization of novel gene therapy treatments. For more information, please visit www.jaguargenetherapy.com and follow Jaguar Gene Therapy on LinkedIn.